The co-primary endpoints were PFS and OS between group A and C for the total patient population, and, in a hierarchical approach, OS between group B and C in patients with Combine Positive Score (CPS) ≥10 and in the total population; this last endpoint was tested only if the PFS and OS was superior in group A compare to group C. CPS was measured as the percentage of PD-L1–positive immune and tumor cells compared to the number of tumor cells (see Table 1 for PD-L1 positivity. The gene discussed is CD274; the disease is neoplasm.